Patient characteristics, disease burden, treatment patterns and outcomes in patients with acromegaly: Real-world evidence from the Malaysian acromegaly registry
doi.org/10.15605/jafes.038.01.06
- Author:
Mohamed Badrulnizam Long Bidin
1
;
Abdul Mueed Khan
2
;
Florence Hui Sieng Tan
3
;
Nor Azizah Aziz
4
;
Norhaliza Mohd Ali
5
;
Nor Azmi Kamaruddin
6
;
Shireene Vethakkan
7
;
Balraj Sethi
2
;
Zanariah Hussein
8
Author Information
1. Hospital Kuala Lumpur, Jalan Pahang, Malaysia
2. Novartis Corporation (M) Sdn Bhd, Petaling Jaya, Selangor, Malaysia
3. Hospital Umum Sarawak, Sarawak, Malaysia
4. Hospital Pulau Pinang, Pulau Pinang, Malaysia
5. Hospital Sultanah Aminah Johor Bahru, Johor Bahru, Malaysia
6. Hospital Canselor Universiti Malaya, Kuala Lumpur, Malaysia
7. Pusat Perubatan Universiti Malaya, Kuala Lumpur, Malaysia
8. Hospital Putrajaya, Putrajaya, Malaysia
- Publication Type:Journal Article
- Keywords:
malaysian registry;
healthcare resource utilization
- MeSH:
acromegaly;
treatment outcomes
- From:
Journal of the ASEAN Federation of Endocrine Societies
2023;38(1):75-80
- CountryPhilippines
- Language:English
-
Abstract:
Objective:This study aims to report the demographic features of patients with acromegaly the disease burden, and the corresponding treatment patterns and outcomes in Malaysia.
Methodology:This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained.
Results:Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 – 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%).
Conclusion:This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.
- Full text:2465-Article Text-23159-1-10-20230518.pdf
